Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878209 | 0.86 | FBP1 (0.64) | FBP1 | |
| SCHEMBL4877432 | 0.84 | FBP1 (0.62) | FBP1RORB | |
| SCHEMBL4878102 | 0.83 | FBP1 (0.62) | FBP1 | |
| SCHEMBL4870431 | 0.82 | FBP1 (0.71) | FBP1 | |
| SCHEMBL4879040 | 0.82 | FBP1 (0.61) | FBP1RORB | |
| SCHEMBL4876731 | 0.82 | FBP1 (0.69) | FBP1 | |
| SCHEMBL4874765 | 0.81 | FBP1 (0.70) | FBP1 | |
| SCHEMBL1256222 | 0.80 | RORB (0.60) | RORB | |
| SCHEMBL4874790 | 0.80 | FBP1 (0.67) | FBP1 | |
| SCHEMBL4876536 | 0.79 | FBP1 (0.76) | FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070868-A1 | Novel Thiazole Inhibitors of Fructose 1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080070868-A1 | Novel Thiazole Inhibitors of Fructose 1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080070868-A1 | Novel Thiazole Inhibitors of Fructose 1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20070225259-A1 | Novel Thiazole Inhibitors of Fructose 1,6-Bishosphatase | METABASIS THERAPEUTICS, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225259-A1 | Novel Thiazole Inhibitors of Fructose 1,6-Bishosphatase | METABASIS THERAPEUTICS, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225259-A1 | Novel Thiazole Inhibitors of Fructose 1,6-Bishosphatase | METABASIS THERAPEUTICS, INC. | 2007-09-27 | — | — | US | disclosed |
| EP-1778250-A2 | NOVEL THIAZOLE INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | Metabasis Therapeutics, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006023515-A2 | NOVEL THIAZOLE INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225259-A1 | Novel Thiazole Inhibitors of Fructose 1,6-Bishosphatase | FBP1, PFKFB1, ALDOA | FBP1 1/4885RORB 2389/4885 |
| US-20080070868-A1 | Novel Thiazole Inhibitors of Fructose 1,6-bisphosphatase | FBP1, ALDOA, SLC5A1 | FBP1 1/4885RORB 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.